Navigation Links
Childers, Schlueter & Smith, LLC Set for Reglan/metoclopramide Jury Trial Involving Woman's Development of Tardive Dyskinesia
Date:7/19/2010

ATLANTA, July 19 /PRNewswire/ -- The law firm of Childers, Schlueter & Smith, LLC of Atlanta, Georgia has announced that a jury trial involving the drug Reglan/metoclopramide will be held during the week of July 26, 2010.  The case is Susan Swicegood v. Pliva et. al. in the United States District Court, Northern District of Georgia, Atlanta Division.

The lawsuit alleges that the drug makers and marketers of Reglan/metoclopramide failed to adequately warn physicians of the long-term dangers associated with taking the drug, specifically, the neurological disorder tardive dyskinesia.

Reglan and its generic equivalent, metoclopramide, are used to treat several types of stomach disorders including nausea and acid reflux. The complaint alleges that Ms. Swicegood's doctor prescribed 10mg Reglan to be taken four times daily. Ms. Swicegood took the generic form of the drug and developed a permanent movement disorder called tardive dyskinesia as a result - a disorder of the nerves in which involuntary, repetitive movements develop in the lower portion of the face and in limbs.

Previous and Pending Reglan lawsuits, which now total over 150 filed, prompted the FDA to change requirements in the labeling of the drug in February 2009 to account for the increased risk of developing tardive dyskinesia from Reglan/metoclopramide use. New rules included a "Black Box" warning about the potential risk of tardive dyskinesia from long-term use. However, the suit alleges that the Physician's Desk Reference used by Ms. Swicegood's doctor was not updated with the new warnings as required by law.  As a result, neither the patient nor her doctor understood the true risk of taking or prescribing the drug.

The lawsuit was filed in the United States District Court, Northern District of Georgia, Atlanta Division. The Defendant in the case is Pliva, Inc. The Civil Action File Number is 1:07-CV-1671. Childers, Schlueter & Smith, LLC will conduct the Reglan/metoclopramide jury trial with its nationally renowned co-counsel of Daniel J. McGlynn of McGlynn, Glisson, and Mouton Law Firm and Bill Curtis of Miller, Curtis & Weisbrod, LLP.

About Childers, Schlueter & Smith:

Childers, Schlueter & Smith is a preeminent Georgia law firm that takes pride in years of experience and exceptional results. For more about the alleged dangers of Reglan/metoclopramide, or to learn more about Childers, Schlueter & Smith, call toll free at 1-800-641-0098 or visit http://www.cssfirm.com.


'/>"/>
SOURCE Childers, Schlueter & Smith, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
2. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
3. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
4. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
5. Robbins & Myers Announces Regular Quarterly Cash Dividend
6. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
7. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
8. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
9. Robbins & Myers Announces Fourth Quarter and Full Year 2009 Results
10. Dynatronics Appoints Douglas Sampson as Vice President of Production and Research & Development
11. Frost & Sullivan Identifies Focus on Quality Management and Adoption of a Full-service Model as Keys to the Growth of the European CRO Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017  Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis instruments and consumables for the medical ... to discuss its financial results for the third quarter ... will be at 4:15 p.m. ET on Thursday, January ... the third quarter fiscal year 2017 after the market ...
(Date:1/19/2017)... , Jan. 19, 2017  Sensus Healthcare, ... device company specializing in the treatment of non-melanoma ... keloids, with superficial radiation therapy, today announced that ... year 2016 financial results on Thursday, February 2, 2017 ... will hold a conference call with the investment ...
(Date:1/19/2017)... Shire plc (LSE: SHP, NASDAQ: ... and Drug Administration (FDA) has acknowledged receipt of the ... for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. ... for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected to ... the designated Prescription Drug User Fee Act (PDUFA) action ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... 2017 , ... "TransFlare 4K Mystique comes with 44 colorful mysterious transitions that ... Christina Austin - CEO of Pixel Film Studios. , TransFlare 4K Mystique contains ... lens flare and light leak transitions have a very high-dynamic range for super smooth ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a ... has set out for each of his children. “The Angel” is the creation of ... Music in New York City, and impassioned writer. , When asked of her new ...
(Date:1/20/2017)... ... January 20, 2017 , ... D R Burton Healthcare Products ... was featured in a study indicating superior performance against competitive products in secretion ... Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the ...
(Date:1/20/2017)... ... 2017 , ... “Knowledge is God’s Lighthouse”: a moving and colorful collection ... is the creation of published author, Gene Gaapf, a retired truck driver, and a ... have been writing since high school and have many different titles,” Gaapf mentions about ...
(Date:1/19/2017)... ... 2017 , ... Today, the Centers for Medicare & Medicaid Services (CMS) announced ... Models (APMs) in 2017. Clinicians who participate in APMs are paid for the quality ... the Administration’s effort to build a system that delivers better care and one in ...
Breaking Medicine News(10 mins):